Effective oral ganciclovir prophylaxis against cytomegalovirus disease in heart transplant recipients
| Autor: | Robert C Lichtenberg, Marc A. Silver, P.C. Barath, C.E Lawless, John A. Robinson, Vijay Yeldandi, G. M. Mullen, P. J. O'Keefe, K. Malinowska |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Ganciclovir
Human cytomegalovirus Adult Male medicine.medical_specialty Time Factors Adolescent medicine.medical_treatment Administration Oral medicine.disease_cause Gastroenterology Antiviral Agents Herpesviridae Drug Administration Schedule Postoperative Complications Betaherpesvirinae Internal medicine medicine Humans Adverse effect Aged Retrospective Studies Heart transplantation Transplantation biology business.industry Middle Aged biology.organism_classification medicine.disease Immunology Cytomegalovirus Infections Injections Intravenous Heart Transplantation Surgery Female Viral disease business medicine.drug |
| Zdroj: | Transplantation proceedings. 30(8) |
| ISSN: | 0041-1345 |
| Popis: | The presented data show the combined sequential use of i.v. G for 14 days followed by PO G for 90 days is a much more effective prophylaxis for CMVD after heart transplantation than use of i.v. G for 14 days followed by PO A for 90 days. A need for hospitalization due to CMVD is significantly reduced by this new strategy. The follow-up in group II is shorter than in group I but is now at least 6 months in group II, without any new cases in the first 6 months after cardiac transplantation. Some currently unknown adverse effect of prolonged PO G, which may be present, is not identified in this analysis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect